Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SUSP-TESTO 100 is an injectable testosterone suspension marketed by Sinovo, a company specializing in performance-enhancing substances. Unlike common esterified forms of testosterone such as cypionate or enanthate, this formulation contains pure, unesterified testosterone crystals in a water-based medium. This allows for rapid absorption into the systemic circulation and immediate physiological activity, as the hormone does not require enzymatic cleavage of an ester to become active. It functions as a potent agonist of the androgen receptor (AR), promoting muscle protein synthesis, nitrogen retention, and the development of male secondary sexual characteristics. It is primarily utilized in non-therapeutic contexts for bodybuilding and athletic performance enhancement due to its rapid onset of action.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SUSP-TESTO 100.